Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
Status:
Completed
Trial end date:
2016-02-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare edoxaban to warfarin (with enoxaparin, if needed). It
will see if edoxaban prevents stroke and other blood clotting problems as well and as safely
as warfarin. People with atrial fibrillation (irregular heartbeat) might be able to join.
Their doctors must plan to use shock to make their hearts beat normally. About 2200 people
from different countries will join. They will have an equal chance of receiving either
treatment. They are anticipated to be in the study for around 82 days. Tests will include
physicals and finger-pricks. Participants will provide blood and urine samples.
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo Inc. Daiichi Sankyo, Inc.
Collaborators:
Covance Quintiles, Inc.
Treatments:
Edoxaban Enoxaparin Factor Xa Inhibitors Vitamin K Vitamins Warfarin